<DOC>
	<DOCNO>NCT02921191</DOCNO>
	<brief_summary>Purpose : With exist recombinant human granulocyte colony-stimulating factor ( G-CSFs ) patent expire FDA approval new biosimilar innovator biologics , patient treat Grade III IV myelosuppressive chemotherapy regimens additional therapeutic option . This observational study describe patient characteristic new user G-CSFs . It describe treatment cohort primary outcome hospitalization febrile neutropenia . The BBCIC use finding descriptive analysis design comparative study evaluate real-world effectiveness safety biosimilar innovator G-CSFs .</brief_summary>
	<brief_title>Descriptive Analysis G-CSF Use Patients With Breast Cancer , Lung Cancer , Lymphoma Treated</brief_title>
	<detailed_description>Additional information : To effectively interpret result descriptive analysis important consider protocol design support hypothesis . This information provide public interest transparency demonstrate BBCIC 's Distributed Research Network 's ( DRN ) ability define exposure , outcome , covariates confounders . When publish , report caution protocol support ability compare safety effectiveness instead use explore feasibility future , detailed comparative analysis well understand capability BBCIC project . Further , report caution information protocol affect use medical product describe way fact BBCIC perform descriptive analysis way suggest safety effectiveness issue product describe .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Individuals baseline period 183 day continuous medical pharmacy coverage precede first prescription fill GCSF Breast lung cancer patient receive first cycle Grade III IV myelosuppressive chemotherapy regimen treat prophylactically GCSF . During baseline 365 day , patient claim ( ) Chemotherapy drug . Skilled nursing facility ( SNF ) hospice care Diagnosis secondary breast cancer diagnosis A second cancer diagnosis ( i.e. , breast , lung , lymphoma ) Bone marrow stem cell transplant Radiotherapy Chemo cycle &gt; First : ( exclude chemotherapy cycle post index GCSF date ) HIV/AIDS Hepatic disease Other nononcology relate neutropenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>recombinant human granulocyte colony-stimulating factor</keyword>
	<keyword>G-CSFs</keyword>
	<keyword>biosimilar</keyword>
	<keyword>biologics</keyword>
	<keyword>High Neutropenia Risk Chemotherapy</keyword>
	<keyword>Biologic Biosimilars Collective Intelligence Consortium</keyword>
	<keyword>bbcic</keyword>
</DOC>